Qiliqiangxin Improves Cardiac Function through Regulating Energy Metabolism via HIF-1α-Dependent and Independent Mechanisms in Heart Failure Rats after Acute Myocardial Infarction.
Yanyan WangMingqiang FuJingfeng WangJingjing ZhangXueting HanYu SongYuyuan FanKai HuJingmin ZhouJun-Bo GePublished in: BioMed research international (2020)
The present study is aimed at investigating whether Qiliqiangxin (QL) could regulate myocardial energy metabolism in heart failure rats after acute myocardial infarction (AMI) and further exploring the underlying mechanisms. AMI was established by ligating the left anterior descending coronary artery in adult male SD rats. AMI rats with ejection fraction (EF) < 50% at two weeks after the operation were chosen as heart failure rats for the main study. Rats were randomized into the sham, MI, MI+QL, and MI+QL+2-MeOE2 groups. The results showed that compared with the MI group, QL significantly improved cardiac function, reduced serum NT-proBNP level, and alleviated myocardial fibrosis. QL also increased myocardial capillary density by upregulated protein expressions of vascular endothelial growth factor (VEGF) and CD31 by regulating the HIF-1α/VEGF pathway. Moreover, QL promoted ATP production, glucose uptake, and glycolysis by upregulating HIF-1α and a series of glycolysis-relevant enzymes in a HIF-1α-dependent manner. QL also improved myocardial glucose oxidation enzyme expression and free fatty acid uptake by a HIF-1α-independent pathway. Our results indicate that QL treatment improves cardiac function through regulating glucose uptake, FFA uptake, and key enzymes of energy metabolism via HIF-1α-dependent and independent mechanisms.
Keyphrases
- acute myocardial infarction
- left ventricular
- heart failure
- vascular endothelial growth factor
- endothelial cells
- coronary artery
- ejection fraction
- percutaneous coronary intervention
- cardiac resynchronization therapy
- aortic stenosis
- blood glucose
- type diabetes
- coronary artery disease
- blood pressure
- randomized controlled trial
- acute coronary syndrome
- pulmonary artery
- atrial fibrillation
- young adults
- binding protein
- metabolic syndrome
- transcatheter aortic valve replacement
- replacement therapy
- pulmonary hypertension
- preterm birth